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Mitochondria are important regulators of macrophage polarisation. Here, we show that
arginase-2 (Arg2) is a microRNA-155 (miR-155) and interleukin-10 (IL-10) regulated protein
localized at the mitochondria in inflammatory macrophages, and is critical for IL-10-induced
modulation of mitochondrial dynamics and oxidative respiration. Mechanistically, the cata-
lytic activity and presence of Arg2 at the mitochondria is crucial for oxidative phosphoryla-
tion. We further show that Arg2 mediates this process by increasing the activity of complex II
(succinate dehydrogenase). Moreover, Arg2 is essential for IL-10-mediated downregulation
of the inflammatory mediators succinate, hypoxia inducible factor 1α (HIF-1α) and IL-1β
in vitro. Accordingly, HIF-1α and IL-1β are highly expressed in an LPS-induced in vivo model of
acute inflammation using Arg2−/− mice. These findings shed light on a new arm of IL-10-
mediated metabolic regulation, working to resolve the inflammatory status of the cell.
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Macrophages are important immune cells that can exerteither pro-inflammatory or anti-inflammatory func-tions, for innate as well as adaptive immune responses1.
Metabolically, it has been shown that in vitro ‘M1-like’ inflam-
matory macrophages utilize aerobic glycolysis for the generation
of ATP. This is accompanied with a downregulation of mito-
chondrial oxidative phosphorylation (OxPhos) and an accumu-
lation of certain metabolites in the tricarboxylic acid (TCA) cycle,
such as citrate and succinate2,3. Conversely, diverse anti-
inflammatory stimuli including IL-10, IL-4, and IL-13 are ‘M2-
like’ anti-inflammatory phenotype inducers. M2-like cells are
shown to favour the use of OxPhos4,5, which has been linked to
specific alterations in macrophage mitochondrial dynamics6–8.
IL-10 is an anti-inflammatory cytokine acting in an autocrine
fashion in macrophages to limit inflammatory responses by
decreasing the production of pro-inflammatory cytokines9,10.
Simultaneously, IL-10 increases anti-inflammatory genes, typi-
cally in a STAT3 dependent manner10–13. Furthermore, inflam-
matory macrophages utilize arginine for the production of nitric
oxide (NO), which IL-10 can limit by inhibiting the transcription
of inducible nitric oxide synthase mRNA (Nos2)14,15 or by
enhancing the degradation of iNOS protein10,16. Concomitantly,
IL-10 increases arginase expression to limit the availability of
arginine for NO production13,17. In fact, IL-10 was shown to
regulate macrophage glycolytic commitment by preserving
OxPhos through its suppression of NO18 or via suppression of
mammalian target of rapamycin (mTOR)19. It has also been
shown that IL-10, via STAT3, inhibits the pro-inflammatory
microRNA miR-15520. IL-10 was shown to modulate miR-155
target genes suggesting a distinct mechanism that IL-10 uses to
maintain an anti-inflammatory state in macrophages20.
Here, we identify Arg2 as one of the most prominent metabolic
genes regulated by the IL-10/miR-155 axis. We also show that IL-
10-mediated induction of Arg2 protein is essential for skewing
mitochondrial dynamics and bioenergetics in inflammatory
macrophages towards an oxidative phenotype, particularly by
enhancing activity of complex II (CII) at the electron transport
chain (ETC). This work highlights Arg2 as a downstream med-
iator of IL-10 and provides a mechanism for its function as a
resolver of inflammation.
Results
Arg2 is positively regulated by IL-10 in inflammatory macro-
phages. We first identified the gene Arg2 when investigating
regulation of inflammatory macrophages at the interface of the IL-
10/miR-155 axis. A microarray was performed to examine gene
expression changes between wild type (WT) murine bone
marrow-derived macrophages (BMDM) stimulated with LPS
(inflammatory) compared to those stimulated with LPS+ IL-10
(anti-inflammatory) or to miR155−/− BMDM stimulated with
LPS, miR-155−/−(LPS) (predicted anti-inflammatory) (Fig. 1a and
Supplementary Fig. 1a). Rotation gene set enrichment analysis
(ROMER) indicated that the highest proportion of genes on this
axis converged on metabolic pathways (Supplementary Fig. 1b). In
particular, Arg2 displayed enhanced expression in both the WT
(LPS+ IL-10) andmiR-155−/−(LPS) groups (Fig. 1b), and was the
only gene with a miR-155 binding site in its 3′UTR (Fig. 1b and
Supplementary Fig. 1c)21. We confirmed Arg2 was a miR-155
target in macrophages by a luciferase assay, where Arg2 3′UTR
activity was significantly suppressed in the presence of a miR-155
mimic, and reciprocally enhanced in the presence of the antag-
omir (Fig. 1c). Importantly, Arg2 protein levels were greater in
miR-155−/−(LPS+ IL-10) compared to miR-155+/+(LPS+
IL-10), as opposed to Arg1 whose expression was consistent
between genotypes (Fig. 1d).
Although IL-10 is broadly known to induce Arg110,13,22, only
one inference suggested an IL-10 mediated increase of Arg2 in
inflammatory macrophages by an affymetrix array10. Here, we
significantly extend those studies by validating upregulation of
Arg2 by exogenous IL-10 in LPS-treated murine and human
macrophages compared to cells treated with LPS or IL-10 alone,
at both the mRNA and protein level (Fig. 1e–h and Supplemen-
tary Fig. 1d). In contrast, Arg1 appears to be synergistically
upregulated by LPS+ IL-10 only in murine macrophages (Fig. 1h
and Supplementary Fig. 1d). The dependency of autocrine IL-10
in Arg2 upregulation was confirmed when LPS mediated
induction of Arg2 was reduced in BMDM treated with an IL-
10Rα blocking antibody (Fig. 1i) and in Il10−/− BMDM
stimulated with LPS (Fig. 1j). Moreover, the addition of
exogenous IL-10 in LPS stimulated Il10−/− BMDM restored
Arg2 expression (Fig. 1j). Additionally, in BMDM treated with
STATTIC, an inhibitor of STAT3, significantly reduced levels of
Arg2 mRNA and protein were observed (Supplementary
Fig. 1e–g).
We next sought to investigate arginase catalytic activity
(conversion of L-arginine to L-ornithine) by measuring the by-
product urea in LPS, LPS+ IL-10, and IL-10 stimulated BMDM.
Firstly, in WT BMDM LPS treatment increased urea production
but this was significantly enhanced by the addition of IL-10
in LPS+ IL-10 treated cells (Fig. 1k), an effect that was lost in
Il10−/− BMDM (Supplementary Fig. 1h). Pharmacological
inhibition of the catalytic activity of arginase using the pan
arginase inhibitor, nor-NOHA, confirmed the dependence of
both isoforms on arginase activity in LPS+ IL-10 stimulated
cells (Supplementary Fig 1i, j). Furthermore, in order to establish
the relative contribution of Arg1 and Arg2, we used siRNAs
specific for each isoform (Supplementary Fig. 1k, l), and
illustrated a reliance on both isoforms in the production of urea
in LPS+ IL-10 treated macrophages (Supplementary Fig. 1m).
Arg1−/− mice die approximately 2 weeks after birth, hampering
the capacity for BMDM harvesting23. However, we confirmed
the contribution of Arg2 to arginine metabolism in Arg2−/−
BMDM where there was a significant loss of urea production in
Arg2−/−(LPS+ IL-10) cells (Fig. 1l). A concomitant increase in
NO levels was also detected (Supplementary Fig. 1n), suggesting
an absence of Arg2 may enhance the availability of L-arginine
for iNOS.
Arg2 is localized at the mitochondria. In a further effort to
identify independent roles for arginase isoforms, we focused on
the fact that only Arg2 contains a mitochondrial targeting
sequence (MTS)24. Although this infers constitutive localization
at the mitochondria, this has not been thoroughly validated in
macrophages25 and translocation to the cytosol has been observed
in endothelial cells26, indicating that Arg2 localization is a
dynamic process influenced by different conditions. Here, we
definitively illustrate mitochondrial Arg2 localization in macro-
phages by employing a variety of techniques, and more specifi-
cally, assess the impact of IL-10 on this process. We firstly showed
that Arg2 is localized to the mitochondria in comparison to Arg1,
utilising an in vitro transcription/translation (IVTT) system
(Fig. 2a). Overexpressing plasmids for Arg1 (pCMV-Arg1) and
Arg2 (pCMV-Arg2) over a time-course of 60 min showed Arg2 is
avidly imported into the mitochondria. However, this was not the
case for Arg1 (Fig. 2a compare lanes 2–4 and 7–9). Furthermore,
Arg2 remained imported following depolarization of the mito-
chondrial membrane via addition of FCCP (lane 10), which may
indicate that Arg2 is localized in the inner mitochondrial mem-
brane (IMM) as proteins targeted to the mitochondrial matrix
require membrane potential to cross the IMM27,28. However,
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future studies will need to confirm the true nature of this
localization.
We next wanted to ascertain if our stimulations induced
translocation of Arg2 to or from the mitochondria (as previously
reported for endothelial cells in response to oxLDL26). We
confirmed with cellular fractionation in BMDM that Arg2 is
localized and upregulated at the mitochondria in response to LPS
+ IL-10 in Il10–/– BMDM (Fig. 2b). This was not the case for
Arg1, which was only detected in cytosolic fractions across
treatments (Fig. 2b). Furthermore, using ImageStreamTM flow
cytometry, Arg2 was predominantly expressed and localized with
the mitochondrial protein, Tom20, especially in LPS+ IL-
10 stimulated cells (Fig. 2c). Quantitative analysis revealed
colocalization of Tom20/Arg2 in quiescent cells was 44.6%
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(Supplementary Fig. 2a), which was boosted to 60% in LPS+ IL-
10 treated BMDM (Supplementary Fig. 2a). In addition, increased
expression and localization of Arg2 at the mitochondria was also
detected in Raw 264.7 macrophages treated with LPS+ IL-10
(Supplementary Fig. 2b).
Arg2 regulates mitochondrial dynamics. Given the considerable
expression of Arg2 at the mitochondria in LPS+ IL-10 cells, we
decided to examine mitochondrial morphology and dynamics
under our experimental conditions. Mitochondrial function is
intimately linked to their plastic structure which continuously
changes according to the needs of the cell29. For example, LPS is a
well-documented inducer of excessive mitochondrial fission29–31,
represented by small, punctate and fragmented mitochondria (≤1
μm). Contrarily, a state of ‘fusion’ in which mitochondria are
elongated (≥3 μm) facilitates mitochondrial respiration and sur-
vival32. Assessing mitochondrial dynamics revealed LPS-only
stimulated cells exhibited significantly increased mitochondrial
fission compared to controls (≤1 μm approx. CTL:16%; LPS:85%)
(Fig. 2d). Remarkably, however, this state of fission was not only
significantly reduced in LPS+ IL-10 (≤1 μm approx. 6%) but
mitochondria were found predominantly in a state of fusion (≥3
μm approx. LPS:10%; LPS+ IL-10:64%) (Fig. 2d). Next, we
examined whether arginase enzymatic activity was essential for
this morphological effect. We saw mitochondrial fusion was
significantly decreased (≥3 μm approx. 22%) in LPS+ IL-10
treated BMDM pre-treated with nor-NOHA. (Fig. 2e and Sup-
plementary Fig. 2c). More importantly, we showed that Arg2–/–
(LPS+ IL-10) cells (≥3 μm approx. 18%) exhibited significantly
lower levels of fused mitochondria compared to Arg2+/+(LPS+
IL-10) cells (≥3 μm approx. 64%) (Fig. 2f and Supplementary
Fig. 2d).
Arg2 increases mitochondrial respiration in macrophages. IL-
10 has been shown to influence mitochondrial features and
associated functions such as mass, membrane potential (ΔΨm)
and oxidative phosphorylation (OxPhos)19. Given the effect of
Arg2 on mitochondrial dynamics, we investigated potential roles
Arg2 may play in these IL-10 driven mitochondrial functions. We
first demonstrated by flow cytometry that Arg2–/– BMDM were
comparable in overall cellular size and intracellular complexity to
Arg2+/+ (Supplementary Fig. 2e, f). Furthermore, we found
mitochondrial mass was unchanged between the genotypes in all
experimental conditions (Supplementary Fig. 2g). However, we
observed that the membrane potential, ΔΨm, was significantly
decreased in Arg2–/–(LPS+ IL-10) cells compared to
Arg2+/+(LPS+ IL-10) (Supplementary Fig. 2h). As membrane
potential is a driving force behind mitochondrial ATP synthesis,
this finding led us to examine the effect of Arg2 on OxPhos. LPS-
stimulated macrophages diminish their commitment to OxPhos
as a means of energy production33 while exogenous IL-10 can
promote OxPhos in LPS-stimulated Il10–/– macrophages19. Cer-
tainly, we validated the ability of exogenous IL-10 to significantly
restore OxPhos in Il10–/– BMDM treated with LPS, as evidenced
by increased basal oxygen consumption rate (OCR), maximal
respiratory capacity (MRC) and OxPhos-induced ATP produc-
tion (Supplementary Fig. 3a, b). However, restoration of these
parameters by IL-10 was significantly reduced in Raw 264.7
macrophages treated with siRNA against Arg2 (siArg2) compared
to non-targeting controls (siNT) (Supplementary Fig. 3c). This
finding was recapitulated in siRNA treated iBMDM (Fig. 3a, b
and Supplementary Fig. 3d) and confirmed in Arg2–/–(LPS+ IL-
10) BMDM (Fig. 3c, d).
Next we investigated the requirement of arginase catalytic
activity in this process, and found that basal OCR and MRC were
significantly blunted in Il10–/– (LPS+ IL-10) cells pre-treated
with nor-NOHA, with a concomitant reduction in OxPhos-
induced ATP (Fig. 3e, f). Similar to BMDM, significantly
downregulated OxPhos was observed in Raw 264.7 macrophages
pre-treated with nor-NOHA (Supplementary Fig. 3e). To under-
stand the relative contribution of Arg1 vs Arg2 on OxPhos, we
looked at their in situ oxidative respiratory parameters in Raw
264.7 by overexpression plasmid studies, confirmed by immuno-
blot analysis (Supplementary Fig. 3f). Mitochondrial respiration
results demonstrated that pCMV-Arg2 significantly boosted
OxPhos (Fig. 3g), as shown by increased OCR parameters
(Fig. 3h). However, no difference was detected between pCMV-
Arg1 and the empty vector control, pCMV-EV (Figs. 3g and h).
Finally, we specifically tested the importance of Arg2’s catalytic
activity by mutating its catalytic site at Histidine-14534 to
Phenylalanine (H145F). An arginase assay confirmed the catalytic
inactivity of the H145F mutant (Fig. 3i), while immunoblotting
illustrated comparable expression to wild-type pCMV-Arg2.
(Supplementary Fig. 3g). Subsequently, we demonstrated that
the catalytic site of Arg2 played a significant role in its regulation
of OxPhos (Fig. 3j), as all parameters of Oxphos were
downregulated in the H145F mutant compared to pCMV-Arg2
(Fig. 3k). Collectively, this is the first report of the Arg2 isoform
influencing oxidative machinery in an immune cell type.
Fig. 1 Arginase-2 is regulated by an IL-10/miR-155 axis in inflammatory macrophages. Macrophages (BMDM, Raw 264.7, or THP-1) were left untreated
or stimulated with either LPS, LPS+ IL-10, or IL-10 alone for 24 h. a Schematic of microarray design. Comparison of gene expression changes between WT
(LPS) BMDM (inflammatory), WT(LPS+ IL-10) BMDM (anti-inflammatory) or miR-155−/−(LPS) BMDM, (predicted anti-inflammatory). b MA plot
illustrating log fold-change between miR-155−/−(LPS) and WT(LPS+ IL-10) activated macrophages with common upregulated (red) and downregulated
(blue) genes. Also shown are common inflammatory and anti-inflammatory genes in macrophages. c Luciferase activity assay of the Arg2 3′UTR reported
as relative light units (RLU) in the presence or absence of miR-155 mimic or inhibitor in Raw 264.7 cells (n= 3 independent experiments). Non-targeting
control (NC) mimic or inhibitor are reported as reference and set at 100%. d Arg2 and Arg1 protein levels in miR-155+/+ and miR-155−/− BMDM.
Representative of n= 3 biological replicates. e RT-PCR analysis of Arg2 and Arg1 mRNA levels in BMDM (n= 3 biological replicates). Data compared by
normalizing to m18s and analyzing relative fold change to unstimulated controls. f Arg2 and Arg1 protein levels in BMDM. Representative of (at least) n= 5
biologically independent experiments. g RT-PCR analysis of Arg2 mRNA levels in THP-1 cells (n= 3 independent experiments. Data points represent
average of technical triplicates per independent experiment). Data were compared by normalizing to m18s, and analyzing relative fold change compared to
unstimulated controls. h–j Arg2 and Arg1 protein levels (representative of n= 3 biological independent experiments) in h THP-1 cells, i BMDM in the
presence or absence of IL-10Ra (anti-IL-10R) antibody at indicated concentrations, j Il10+/+ and Il10−/− BMDM. k, l Urea as output of arginase activity in:
k wild-type BMDM (n= 6 biological replicates), and l Arg2+/+ vs Arg2−/− BMDM (n= 3 biological replicates). c, e, g, k, l Data shown is mean with error
bars representing ± SEM. Data were analysed by c Ordinary one-way ANOVA, and e, l two-way ANOVA, followed by c, e Tukey’s and l Sidak’s multiple
comparisons post-hoc test. g, k Data for LPS vs LPS+ IL-10 compared by paired two-tailed t-test. P-values are indicated on graphs for statistically
significant comparisons.
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Succinate dehydrogenase/complex II activity is increased by
Arg2. Having established that Arg2 boosts oxidative metabolism
at the mitochondria, we wanted to unravel the details of this
process and hence, looked towards the TCA cycle and ETC.
Firstly we explored the impact of IL-10 on general TCA cycle
metabolites by utilizing unbiased gas chromatography-tandem
mass spectrometry (GC-MS). We observed that compared to
controls, LPS+ IL-10 mitochondrial wild-type BMDM pellets
exhibited significantly increased levels of fumarate and malate
(Supplementary Fig. 4a), two metabolites downstream of enzyme
succinate dehydrogenase (SDH). This was corroborated by
another study demonstrating significantly decreased levels of
fumarate and malate in Il10–/– BMDM in response to LPS,
compared to their wild-type counterparts18.
SDH is a bi-functional enzyme that acts as a central component
of the TCA cycle, and also serves as complex II (CII) at the ETC.
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To investigate the function of the ETC in a normal structural
context, we examined individual complex activity by measuring
the oxygen consumption rate (OCR) of permeabilized cells
following treatment with Glutamate and Malate for complex I
(CI), and Succinate for CII35. The OCR by CI and CII was
significantly upregulated in LPS+ IL-10 BMDM compared to
unstimulated or LPS-stimulated cells (Fig. 4a). A possible role for
IL-10 on complex activity was confirmed in Il10–/– BMDM where
significantly reduced CI and CII activity was detected in resting
Il10–/– cells compared to wild type controls (Supplementary
Fig. 4b). Next, it was important to examine any impact of Arg2 in
this setting. Interestingly, a significant decrease only in CII-
specific OCR was detected in quiescent Arg2–/– compared to
Arg2+/+ BMDM, whereas CI specific OCR was comparable
between genotypes (Fig. 4b). Furthermore, addition of exogenous
IL-10 failed to boost CII-specific OCR in Arg2–/–(LPS+ IL-10)
cells comparatively (Fig. 4c). We also observed a significant gene
dosage effect when comparing LPS+ IL-10 treatments in Arg2
homozygous (Arg2+/+), heterozygous (Arg2+/–) and deficient
(Arg2–/–) BMDM (Fig. 4d). Conversely, overexpression of Arg2 in
Raw 264.7 macrophages boosted CII-dependent OCR (Fig. 4e).
This was significantly blunted in the cells expressing the H145F
catalytic mutant, demonstrating the importance of Arg2’s
catalytic activity in this process. Importantly, we confirmed that
overexpression of Arg1 had no significant impact on CII activity
relative to empty vector (pCMV-EV) control (Fig. 4e).
In an effort to fully validate our findings with respect to Arg2
and CII activity, we also measured the reduction of MTT to
formazan, a common assay for SDH activity36, which showed
that Arg2–/– BMDMs had significantly lower levels of SDH
activity in both resting and LPS+ IL-10 treatment conditions
(Fig. 4f). No difference was observed between Arg2+/+ and
Arg2–/– after LPS-only stimulation in this assay. The treatment of
cells with the SDH inhibitor dimethyl malonate (DMM), as a
positive control for the assay, reduced SDH activity in both
genotypes to below baseline (Fig. 4f). Similar to our flux analyser
experiments, overexpression of Arg2 in Raw 264.7 macrophages
boosted CII activity in an MTT assay, and this was significantly
blunted in H145F expressing cells (Supplementary Fig. 4c).
Finally, we interrogated CII specific activity using a single
wavelength spectrophotometer technique and expressing it as a
ratio to citrate synthase (CS) specific activity in order to
normalize activities to mitochondrial mass, as previously
described37. Results demonstrated that CII specific activity was
significantly decreased in resting Arg2–/– BMDM compared to
Arg2+/+ controls (Fig. 4g). Additionally, exogenous IL-10 could
significantly restore CII specific activity in Arg2+/+ (LPS+
IL-10) cells when compared to Arg2+/+ (LPS). However, this
ability of IL-10 to restore CII specific activity was lost in Arg2–/–
(LPS+ IL-10) BMDM (Fig. 4g). These results implicating a role
for Arg2 in CII specific activity were upheld when measuring
cellular succinate and fumarate in LPS+ IL-10 Arg2–/– BMDM
compared to wild-type controls. Here we demonstrated that IL-
10 reduced overall succinate (Fig. 4h) and boosted fumarate
levels in LPS+ IL-10 stimulated BMDM compared to LPS
alone (Fig. 4i). This effect was once again lost in Arg2–/–(LPS+
IL-10) BMDM (Fig. 4h-i).
Arg2 regulates HIF-1α and IL-1β during acute inflammation.
The mechanism of LPS-stimulated breaks in the TCA cycle and
abnormal ETC activity are broadly considered inflammatory38. In
such instances, studies have reported an increased inflammatory
phenotype due to direct generation of mitochondrial ROS
(mtROS). This has been intimately linked with the stabilisation
of HIF-1α, increased production of cytokine IL-1β, and a
reduced anti-oxidant response2,39. We detected a significant
increase in mtROS in Arg2–/–(LPS+ IL-10) BMDM compared to
Arg2+/+(LPS+ IL-10) (Fig. 4j) along with enhanced protein
levels of HIF-1α in Arg2–/–(Fig. 4k). Importantly, examination of
IL-1β levels under our conditions revealed that the suppressive
effect of IL-10 on IL-1β in Arg2+/+(LPS+ IL-10) cells was
completely lost in Arg2–/–(LPS+ IL-10) (Fig. 4l). Notably, there
were no significant differences in TNF or IL-6 levels between
Arg2+/+(LPS+ IL-10) and Arg2–/–(LPS+ IL-10) (Supplementary
Fig. 4d). Furthermore, reduced levels of Nrf2, a transcription
factor known to induce expression of anti-oxidant genes,
was detected in Arg2–/– cells across treatments (Supplementary
Fig. 4e).
These findings suggested that IL-10 works through Arg2 at the
mitochondria to mediate its anti-inflammatory effects on IL-1β
production. Next, we examined whether Arg2 is limited
in situations where IL-10 is compromised by performing an
in vivo LPS challenge in Il10+/+ and Il10–/– mice. As expected,
TNF, IL-6 and IL-1β protein levels were significantly increased in
the peritoneal lavage of Il10–/– (Supplementary Fig. 4f). Interest-
ingly, Arg2 mRNA levels were reduced significantly in Il10–/–
PECs (Supplementary Fig. 4g) and there was an indicated absence
of Arg2 protein in tissue taken from the spleen in Il10–/– with no
protein expression changes apparent in Arg1 (Supplementary
Fig. 4h). Finally, we examined responses after an in vivo LPS
challenge in Arg2+/+ and Arg2–/– mice. We observed that
comparable to our ex vivo results in primary BMDM, there was
significantly enhanced HIF-1α expression in spleens of Arg2–/–
mice (Fig. 4m). Furthermore, even though there was a significant
Fig. 2 Arginase-2 regulates dynamics at mitochondria in response to IL-10 in inflammatory macrophages. a IVTT assay for mitochondrial import of
pCMV-Arg1 and pCMV-Arg2. Gels were exposed to phosphor-scene for detection of imported proteins. 1 μl of complete IVTT protein was loaded as input
control (lanes 1 and 6). Time course over 60min showing bands representing proteins bound to and found inside the mitochondrial membrane. FCCP is
used as a depolarising control. Radiograph representative of three experiments ran and processed in parallel. Graph shows densitometry analysis of the
pooled experiments by measuring relative expression. b Immunoblot of Arg1 and Arg2 in fractionated Il10–/– BMDM that were unstimulated (CTL), or
stimulated with LPS, LPS+ IL-10, or IL-10 alone. VDAC and β-tubulin are used as mitochondrial and cytoplasmic controls, respectively. Representative of
three independent experiments. c ImageStream showing colocalization levels of Tom20 and Arg2 in BMDM that were unstimulated (CTL), or stimulated
with LPS, or LPS+ IL-10. (Left) Representative images shown from ~1000 events. Channels shown are bright field (Ch01), Tom20 (green/Ch02), Arg2
(red/Ch11), and a merge. Original magnification, ×60. (Right) Graph showing colocalization index of Tom20 and Arg2 in the different treatments over two
independent biological experiments. Each data point represents median index of ~1000 processed images. d–f BMDM were either left unstimulated (CTL),
or stimulated with LPS, LPS+ IL-10 or IL-10 alone, and stained with MitoTracker Red-CMXRos. Mitochondrial morphology was observed by confocal
microscopy. Lower panels show a higher magnification of the image within the white squares. Arrows show mitochondrial fusion and fission. Graphs show
results of mitochondrial morphology analysis as a mean of n= 3 independent biological experiments. Scale bars represent 5 µm. d Wild-type BMDM,
e BMDM pre-treated with DMSO or nor-NOHA and f Arg2+/+ and Arg2–/– BMDM. a, d–f Data shown with error bars represents ± SEM. d–f Statistical
significance was determined using two-way ANOVA with Tukey’s post-hoc test for multiple comparisons. P-values are indicated on graphs where there is
significance between elongated mitochondrial fractions.
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increase in IL-10 secretion in Arg2–/– mice in the peritoneal
lavage, IL-1β secretion levels remained significantly higher in
these mice compared to wild-type mice (Fig. 4n). Interestingly,
this result was mirrored in vitro following siRNA knockdown of
Arg2 in LPS+ IL-10 treated iBMDM (Supplementary Fig. 4i).
These results collectively indicate that the suppressive effect of IL-
10 on IL-1β is lost in the absence of Arg2.
Discussion
Here, we show that IL-10 mediated upregulation of Arg2 is
essential for skewing mitochondrial dynamics and bioenergetics
in inflammatory macrophages towards an anti-inflammatory,
oxidative phenotype. This work is supported by previous
experiments conducted in H.pylori mediated gastritis where
macrophages from Arg2 deficient mice presented with a more
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inflammatory phenotype, including increased NO and pro-
inflammatory cytokine milieu40. We show that IL-10’s enhance-
ment of Arg2 favours mitochondria in a state of fusion. In sup-
port of this finding, a positive correlation between systemic IL-10
levels in 175 healthy human patients and genes involved in
mitochondrial fusion was previously reported41. Certainly,
mitochondrial dynamics, specifically fusion, has been shown to
influence OxPhos42,43. This is linked with our other main finding
that Arg2 facilitates oxidative respiration via its impact on CII
activity at the ETC. Interestingly we found these effects to be, at
least in part, dependent on Arg2’s catalytic activity, suggesting
ornithine production may play an important role in this
process. Previous work by others has highlighted that IL-4
upregulation of ornithine is essential for hypusination of the
eukaryotic translation initiation factor 5a (eIf5a), which works to
maintain integrity of mitochondrial TCA cycle and OxPhos
proteins44. Whether Arg2’s impact on mitochondrial respiration
is dependent on the production of ornithine requires further
investigation.
As evidenced by global metabolomics studies, macrophages
fluctuate their TCA cycle metabolites in response to inflammatory
stimuli45. Specifically, LPS-induced inflammatory macrophages
increase their succinate levels with decreased alpha-ketogluterate
levels. Work from Baseler et al.18 demonstrated that the LPS-
induced accumulation in succinate in wild-type BMDM was
abolished in Il10–/– BMDM, yet the reductions of alpha-keto-
gluterate, indicative of the LPS-induced “TCA break”, remained
completely intact18. This suggests that autocrine IL-10 acts to
relieve the TCA cycle “break” by increasing metabolites down-
stream of succinate, such as fumarate and malate. In that regard,
SDH, a central enzyme of the TCA cycle, converts succinate to
fumarate, and is shown to be inhibited in LPS-stimulated mac-
rophages39,46. Adding to these studies, we have shown that IL-10
decreases succinate, enhances SDH/CII activity and increases
fumarate production in inflammatory macrophages, an effect we
demonstrate to be dependent on Arg2. Moreover, we show that in
Arg2–/–, HIF-1α and IL-1β expression is elevated. This is inter-
esting considering excess succinate can lead to HIF-1α stabiliza-
tion2, while patients harbouring mutations in SDH have increased
HIF-1α activity47,48 and circulating succinate levels49. Collec-
tively, our work demonstrates that Arg2 is integral in resolving
the inflammatory state of the cell.
The fumarate analogue dimethyl fumarate, DMF, is an
immunomodulatory drug used for the treatment of inflammatory
disorders like psoriasis and multiple sclerosis (MS). Furthermore,
monocytes from DMF-treated relapsing-remitting MS patients
have decreased expression of the pro-inflammatory miR-15550.
DMF has also been shown to reduce pro-inflammatory cytokines
such as IL-1β51,52, enhance mitochondrial oxidative respiration53
and boost the anti-oxidant Nrf2 pathway54. In our studies, we
show a similar profile with Arg2, where we observed enhanced
Arg2 in miR-155−/− macrophages. Furthermore, a loss of Arg2 in
LPS-stimulated macrophages resulted in increased mtROS, HIf-
1α and IL-1β secretion, along with reduced Nrf2 expression,
despite the presence of exogenous IL-10. Certainly, investigating
metabolic processes has led to the discovery of therapeutic
metabolites55 and a better understanding of the mechanisms of
action for current immunomodulatory drugs. Considering IL-10
has had a checkered history as a therapeutic agent, one can
envision that modulation of its targets, like Arg2, could provide
an alternative route for the treatment of inflammatory disorders.
We currently await further analysis of this metabolic enzyme as a
regulator of immunity.
Limitations of the study: Since its discovery, studies have
postulated the likelihood of alternative functions for Arg2, the
lesser studied arginase isoform. It is intriguing that high expres-
sion of the Arg2 isoform at the mitochondria, can facilitate an
increase in SDH activity to impact on the inflammatory status of
the cell. Future studies should focus on the potential interactions
between SDH and Arg2 at the macrophage’s mitochondria, and
more broadly in other cell types.
Methods
Mice. All mice were bred and housed in on-site barrier-controlled facilities having
a 12-h/12-h light/dark cycle with ad libitum access to food and water. Breeding was
approved by the Ethics Committee of the Royal College of Surgeons in Ireland
(REC-842), under license from the Ireland Health Products Regulatory Authority
(AE19127/001) and conformed to the Directive 2010/63/EU of the European
Parliament. miR155−/− C57BL6/J, Arg2−/− C57BL6/J and wild-type (WT)
C57BL6/J mice were all purchased from the Jackson Laboratories. Il10−/− mice
were kindly provided by Ed Lavelle (Trinity College Dublin, Dublin, Ireland).
Il10−/− mice were originally from the Jackson Laboratories (Bar Harbor, Maine)
and bred in‐house.
LPS challenge in vivo. All mice were on a C57BL/6J background, with wild‐type
mice obtained from the Bioresources Unit, Trinity Biomedical Sciences Institute.
Il10−/− mice were housed in the Bioresources Unit, Trinity Biomedical Sciences
Institute in Trinity College Dublin (TCD). Wild type and Arg2−/− littermate mice
were housed in the BRF unit at the Royal College of Surgeons in Ireland. Mice were
used at 8-12 weeks of age. Animals were maintained according to the regulations of
the Health Products Regulatory Authority (HPRA). Animal studies were approved
by the TCD and RCSI Animal Research Ethics Committee (Ethical Approval
Number 091210) and were performed under the appropriate licence (Licence
Number AE19136/P079 for Il10−/− mice and A19127-P045 for Arg2−/− mice).
Age matched female mice were injected by the intraperitoneal (i.p.) route with
10 mg/kg of LPS (E. coli 0111:B4, Invivogen) and culled after 8 h. To detect
Fig. 3 Arginase-2 enhances oxidative phosphorylation in inflammatory macrophages. a–h, j, k Oxygen consumption rates (OCR) were assessed by real-
time metabolic flux assay by addition of Oligomycin (1 µM), FCCP (0.9 µM), and Rotenone+Antimycin A (Rot/Ant A) (0.5 µM) sequentially. a (Left)
unstimulated siNT and siArg2 immortalized BMDM (iBMDM) cells and (right) LPS and/or LPS+ IL-10 treated siNT vs siArg2 iBMDM (representative of
n= 2 biological experiments). b, d, f, h, k Quantitative changes for the basal oxygen consumption rate (basal OCR), maximal respiratory capacity (MRC),
and Oxphos-induced ATP levels. b LPS and LPS+ IL-10 treated iBMDM cells that were either transfected with siNT or siArg2. Data points shown are
pooled 15–20 technical replicates of two independent experiments. c Arg2–/– BMDM (trace representative of n= 3 biological repeats). d Quantitative
changes in oxidative parameters for unstimulated, or LPS/ LPS+ IL-10 stimulated Arg2–/– BMDM (n= 3 biological experiments). e Il10–/– BMDM (left)
unstimulated, or (right) LPS/LPS+ IL-10 stimulated (n= 3 biological experiments). Cells were either pre-treated with DMSO or with 150 μM nor-NOHA
for 1 h before addition of IL-10 and/or LPS stimulations. f Quantitative changes in Il10–/– BMDMs pre-treated with DMSO or nor-NOHA in oxidative
parameters for LPS+ IL-10 treated cells. Data points are biological replicates (n= 3). g Raw264.7 macrophage expressing pCMV-EV, pCMV-Arg1 or
pCMV-Arg2. Trace representative of three independent experiments. h Quantitative oxidative parameters changes in Raw264.7 cells transfected with
overexpression plasmids from (g). Data points are three independent experiments (n= 3). i–k Raw 264.7 macrophage expressing pCMV-EV, pCMV-Arg2
or catalytic dead mutant pCMV-H145F. i Arginase activity assay. Data points indicate three independent experiments. j Mitochondrial OCR trace
representative of two independent experiments. k Arg2 vs H145F OCR parameters. Data points show pooled 15–20 technical replicates from two
independent experiments. a–k Data is presented for all traces and scatter plots as mean ± SEM. d, f, h Each biological or independent data point shown had
10–20 technical replicates. Data were analysed for statistical significance using a two-tailed Student’s t-test, and b, I, k using ordinary one-way ANOVA
with Tukey’s post-hoc test for multiple comparisons. Respective p-values are indicated on graphs for results that were statistically significant.
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cytokines, peritoneal fluid and sera were collected 8 h following i.p. injection of LPS
and stored at −80 °C. IL-1β was quantified by ELISA (R&D Systems). Levels of
TNF, IL-6, IFNγ were calculated by cytokine bead array using the mouse inflam-
mation kit (BD Biosciences). Peritoneal cells (PECs) were isolated by flushing the
peritoneum cavity with PBS containing 5 mM EDTA. Cells were centrifuged and
total RNA isolated using the RNeasy Plus Mini kit (Qiagen) and stored at −80 °C.
Spleens were excised, cut in half, snap-frozen in liquid nitrogen, and stored at
−80 °C until time of assay. RNA was extracted from one half of the spleen by
TRIzol extraction and the second half homogenised, assayed for protein quantifi-
cation by BCA assay (Pierce) and western blotting. The yield and purity of RNA
from spleen and PEC samples was determined using a Nano-Drop 1000 Spec-
trophotometer (VICTOR3000). RNA was converted to cDNA using a reverse
transcription kit (Applied Biosystems). mRNA expression of Tnf, Il1b, Arg2, Inos
and Il6 was determined by Real-time quantitative PCR (RT-PCR) using SYBR
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Green probes on a 7900 HT Real-Time PCR System (Applied Biosystems). Fold
changes in expression were calculated as described below.
Bone marrow-derived macrophage generation. Bone marrow was isolated from
6 to 12 weeks old adult female littermates. Mice were euthanized in a CO2 chamber
and death was confirmed by cervical dislocation. Femurs and tibias were isolated in
sterile conditions, and the bone marrow was flushed out using Dulbecco’s Phos-
phate Buffered Saline (DPBS). Marrow was spun and incubated with red blood cell
(RBC) lysis buffer (Sigma) to remove red blood cells. A single cell suspension was
prepared by passing the cells through a 70 μm cell strainer (Corning). They were
then plated in 10 cm petri dishes in complete DMEM (Dulbecco’s Modified Eagle
Medium (Sigma-D5796) supplemented with 10% heat-inactivated Fetal Bovine
Serum (FBS) (Sigma-F9665) and 1% Penicillin/Streptomycin (100 U/ml) (Sigma).
20% L929 cell supernatant was also added to the culture to induce BMDM dif-
ferentiation via MCSF, after which cells were incubated for 6 days at 37 °C and 5%
CO2 levels. Cells were counted and tested for viability using Trypan Blue staining
(Invitrogen) and a haemocytometer. They were then re-plated for experiments in
complete DMEM supplemented with 10% L929 cell supernatant. Unless stated
otherwise, 5 × 105 cells/ml were used for ex vivo experiments.
Cultured cell lines. Raw264.7, L929, and THP-1 cultured cell lines were obtained
from American Type Culture Collection (ATCC) and cultured as suggested by the
supplier. The immortalised BMDM (iBMDM) were a kind gift from Prof Luke O’
Neill, Trinity College Dublin, as used in previous studies56,57. Cells were routinely
tested to be Mycoplasma negative. They were incubated in 37 °C with 5% CO2
levels. Cell viability was determined using Trypan Blue and counted with a hae-
mocytometer. Raw 264.7 and iBMDM cells were passaged every second and fifth
day (1:5), respectively in T75 flasks. They were cultured in complete DMEM
(supplemented with 10% heat-inactivated FBS and 1% penicillin/streptomycin). All
experiments were carried out in early passage numbers, with passage number not
exceeding 11 at most. Unless stated otherwise, Raw264.7 cells were plated at a
density of 1 × 106 cells/ml and iBMDM were plated at a density of 5 × 105 cells/ml
for in vitro experiments. THP-1 cells were cultured in complete RPMI 1640
(Sigma) supplemented with 2 mM L-glutamine, 10% FBS, and 1% penicillin/
streptomycin. They were plated at a density of 2.5 × 105 cells/ml and differentiated
using 10 ng/ml phorbol-12-myristate-13-acetate (PMA) (Sigma) for 7 h, after
which the media was replaced with PMA-free medium.
L929 cells were passaged every second day (1:5) in T175 flasks. They were
cultured in RPMI-1640 containing 10% heat-inactivated FBS and 1% penicillin-
streptomycin. To generate L-cell supernatant for BMDM differentiation, 20 × 106
cells were plated in 40 ml of complete RPMI-1640 in T175 flasks for 10 days after
which the media was filtered and frozen at −20 °C until use.
Stimulations. Fresh media was added to the cells before stimulation experiments.
Recombinant mouse IL-10 (R&D Systems) from a 1 mg/ml stock was diluted to a
20 μg/ml working stock in 0.1% BSA solution. It was then added to cells at a final
concentration of 20 ng/ml (and 100 ng/ml for metabolic studies). LPS (Sigma E.coli
O111:B4) was diluted from stock concentration of 1 mg/ml in complete DMEM,
and used at a final concentration of 100 ng/ml. For LPS+ IL-10 treatments, cells
were pre-incubated for five minutes with IL-10 prior to the addition of LPS. Cells
were typically stimulated for 24 hours before conducting further assays. Inhibitor
experiments involved pre-treatment before LPS/IL-10 addition. Cells requiring
incubation with inhibitor nor-NOHA (150 μM) (Cayman Chemicals) were pre-
treated 1 h prior to stimulation. Dimethyl Sulfoxide (DMSO) and/or DPBS (Sigma)
were used as controls for inhibitor experiments. For THP-1 cells, 100 ng/ml human
recombinant IL-10 (R&D Systems) was used.
Affymetrix array. Primary BMDM from wild-type (WT) and miR-155 knockout
animals (KO) were stimulated in biological duplicates with LPS (100 ng/ml) or LPS
+ IL-10 (20 ng/ml) to generate four groups as follows: WT.LPS (n= 2), WT.LPS.
IL-10 (n= 2), KO.LPS (n= 2) and KO.LPS.IL10 (n= 2). RNA was extracted using
the RNeasy mini kit (Qiagen) and sent to Almac Diagnostics for Affymetrix
microarray analysis. Spectrophotometer QC was performed to assess the con-
centration and purity of the samples and Bioanalyzer QC was performed to assess
the integrity of the samples. All eight samples were found to meet the QC
requirements for downstream array processing. All samples were amplified using
the NuGEN’s Ovation RNA Amplification System V2 with the Ovation WB
Reagent. Following amplification, all generated cDNA samples were quality con-
trolled using both the spectrophotometer and the Agilent 2100 Bioanalyzer. All
samples passed the quality assessment. In total eight samples proceeded to be
fragmented and labelled using the NuGEN Encore Biotin module, before being
hybridised onto Mouse Genome 430_2 array in accordance with the NuGEN
guidelines for hybridisation onto Affymetrix GeneChip® arrays. Array image
analysis performed on CEL files confirmed no surface or background artefacts. No
outliers were identified as examined by measuring parameters such as background
intensity, Raw noise (Q) value, scaling factor and GAPDH/Actin ratio.
Bioinformatic Analysis raw data was RMA normalised using the affy package58.
Data quality was assessed by box plots of expression values before and after
normalisation. Differential expression analysis was performed using the limma
package59. Samples were assigned to treatment groups and a linear model fit using
the lmFit function. Mouse donor was incorporated as a blocking factor in the linear
model, with inter-subject correlation obtained using the duplicate Correlation
function60. Y-linked genes and Xist were excluded from differential expression
analyses. Moderated t-statistics were calculated for WT.LPS.IL10 versus WT.LPS
and KO.LPS versus WT.LPS using the eBayes function61. Differentially expressed
probes were selected using an unadjusted p-value < 0.05 and an absolute log2(fold
change) >1. Gene set enrichment analysis was performed using the romer
function59,62 using the C5 Gene Ontology (GO) gene sets63,64 from the Molecular
Signatures Database65.
Metabolomics. 5 × 106 BMDM were plated in complete DMEM in T-25 flasks
(25 cm2). Cells were left untreated, treated with LPS (100 ng/ml) in the presence or
absence of IL-10 (20 ng/ml), or IL-10 alone for 20 h. Cells were scraped in 600 μL
80% (v/v) MeOH and cell pellets frozen at −80 °C for 48 h. For extraction cells
were pelleted, washed twice with 80% methanol. Extract was dried in a speed-dry
evaporator and afterwards stored at −80 °C till processing. Intracellular TCA cycle
intermediates were quantified using GC-MS. Stable isotope labelled standards were
added to the cell lysates, which were dried (CombiDancer Hettich AG) and sub-
jected to methoximation and silylation. Then, 1 μl of the derivatized sample was
injected using splitless injection mode. Gas chromatography–mass spectrometry
(GC-MS) data were analysed using the software Mass Hunter (version B.07.01/
Build 7.1.524.0). Quantification was achieved by individual calibration curves based
on the analyte to internal standard area ratio66.
Mitochondrial isolation. BMDM from bacterial 10 cm dishes were harvested,
washed in DPBS, and resuspended in 3 ml of Solution A (20 mM HEPES pH 7.6,
220 mM mannitol, 70 mM sucrose, 1 mM EDTA, 0.5 mM PMSF, and 2 mg/ml
BSA) (Sigma). Cells were left on ice for 15 min in Solution A and then homo-
genized in a glass homogenizer with a Teflon pestle, giving the cells about
60 strokes. Homogenates were then centrifuged at 800 × g for 10 min at 4 °C to
pellet non-lysed cells, cell debris, and nuclei. The supernatant was retained and
centrifuged at 12,000 × g for 20 min at 4 °C for 15 min. The supernatant was then
removed and the pellet was resuspended in ~0.8 ml solution B (Solution A without
BSA) and recentrifuged at the same speed. The step was repeated twice more and
Fig. 4 Arginase-2 influences complex-II activity and regulates IL-1β secretion. a–e XFe96 based comparison of complex I and/or complex II specific OCR in
untreated (CTL) BMDM or stimulated cells (with LPS or LPS+ IL-10 for 24 h). Data plotted as oxygen consumption rate percentage (OCR%) increase after
addition of substrate: a wild-type cells. n= 3 (complex I) and n= 7 (complex II) biological replicates. b Quiescent wild-type (Arg2+/+) vs Arg2–/–, c CTL vs
stimulated Arg2–/–, d LPS+ IL-10 stimulated Arg2+/+, Arg2+/–, and Arg2–/–; b–d Data shown are biological n= 3. e Complex II specific OCR in Raw 264.7
overexpressing pCMV-SPORT6 plasmids for EV (empty vector), Arg2, H145F, and Arg1. Data show 20 technical replicates (for H145F and Arg1) and 40
technical replicates (for EV and Arg2) over two independent experiments. f SDH activity as determined by MTT assay in Arg2+/+ and Arg2–/– BMDM. SDH
inhibitor dimethylmalonate (DMM) used as a control (n= 3 biological replicates). g Complex II specific activity measured by UV-VIS spectrophotometry in
lysates from Arg2+/+ and Arg2–/– BMDM. Activity was normalized to citrate synthase (CS) as control (n= 3 biological triplicates), h–l Comparison of wild-type
(Arg2+/+) and Arg2–/– BMDM for levels of h succinate, i fumarate, j mitochondrial ROS (mtROS) by staining with mitoSOX, k protein expression for Hif-1α,
Arg2, Arg1, and β-tubulin (as loading control); l IL-1β ELISA comparing secretion levels in supernatants. h–j, l n= 3 biological replicates, and k representative of
n= 3 independent experiments; m, n Arg2+/+ and Arg2–/– C57Bl/6J mice were given i.p injection of LPS at 10mg/kg for 8 h: m (Left) Hif-1α, Arg2, and
β-tubulin in spleen. Blot representative of six mice each from wild-type (WT) and Arg2–/–. (Right) densitometry analysis showing relative expression levels of
Hif-1α (n= 6); n IL-1β, IL-10, and IL-6 secretion levels in peritoneal lavage (n= 6 biological replicates). a–j, l–n Data are presented for scatter plots as mean ±
SEM. Data were analysed by a–g, l ordinary one-way ANOVA with Tukey’s multiple comparisons, h, j, n two-tailed t-test with Welch’s correction, and I,m two-
tailed paired t-test. Wherever significant, exact p-value is given on the figure.
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the final pellet was resuspended in 100 μl solution B. The amount of mitochondrial
protein was quantified using a BCA assay.
Mitochondrial Import assays. In vitro transcription/translation (IVTT) reactions
were performed using an RNA polymerase with SP6 promoter transcriptional
compatibility to our pCMV plasmids. pCMV-Arg1 or pCMV-Arg2 were used as
templates in separate IVTT reactions with S35 Met and Cys to generate radio
labelled protein. Mitochondria were isolated and IVTT protein added to mito-
chondrial extracts in import buffer and incubated for 60 min at 37 °C. Samples
were then were run on a gel, including a lane for complete IVTT protein as input
control (In). Gels were exposed to phosphor-scene for detection of imported
proteins. Samples were treated with 25 μM mesoxalonitrile 4-
trifluoromethoxyphenylhydrazone (FCCP) to depolarise mitochondrial mem-
branes over a time course of 60 min. After the import assay was done, an SDS-
PAGE gel was run, which was dried for imaging with a phosphoimager.
siRNA-induced knockdown. Accell® siRNA against Arg2 was obtained from
Dharmacon (GE Healthcare; EQ-040721-00-0002) in dried-down format (2 nmol/
siRNA: set of 4 siRNAs). Other reagents from Dharmacon (CK-005000-R1-02)
included Accell siRNA delivery media and Accell non-targeting control kit siRNA
(5 nmol/siRNA; set of 4 siRNAs). For siRNA stock preparation, 5× Accell siRNA
Buffer (provided with the Accell non-targeting control kit) was diluted to 1×
siRNA Buffer using RNAase-free water under sterile conditions. 100 µM of stock
siRNA solutions were prepared using 1X siRNA Buffer. The stock solutions were
placed on a shaker for 60 minutes at 37 °C when reconstituted for the first time. For
experiments, 4 × 105 Raw 264.7 or 2.5 × 105 iBMDM cells were plated per well in a
24-well plate in complete DMEM and left to propagate overnight in the incubator.
The next day media was removed from the cells and they were transfected using
newly reconstituted siRNA at 1 µM diluted in fresh Accell delivery media that was
supplemented with 2.5% heat-inactivated FBS. The cells were incubated at 5% CO2
and 37 °C for the next 48 h, after which they were washed, collected, and counted
for number and viability using Trypan Blue (Invitrogen). This allowed only viable
cells to be plated at the appropriate cell numbers for another 24–48 h in fresh
complete DMEM, and were then treated according to the assay being conducted.
pCMV-SPORT6 transient transfection. 1.5 × 106 Raw-264.7 cells were seeded in
a 6-well plate in complete DMEM and left overnight to propagate. The following
day, fresh serum-free DMEM (without antibiotic) was added to the cells for
transfection. Overexpression plasmids were purchased as pCMV-SPORT-6-Arg2
and pCMV-SPORT6-Arg1 (Invitrogen). They were transfected at 500 ng/well in
the respective wells using Lipofectamine 3000 (Invitrogen). For control wells, an
empty vector pCMV-SPORT6 plasmid was used. Cells were incubated at 37 °C and
5% CO2 for 4 h with the transfection mix in serum and antibiotic free media, after
which media was replaced with complete DMEM. Cells were incubated for a
further 24 h for Immunoblotting. For metabolic profiling assays, cells were scraped
24 hours post-transfection, counted for number and viability and transferred to
XFe96-well plates (Agilent) for another 24 h before conducting the assay.
Immunoblotting. Cells were resuspended in low-stringency lysis buffer (50 mM
HEPES (pH 7.5), 100 mM NaCl, 10% glycerol (v/v), 0.5% Nonidet P-40 (v/v), 1
mM EDTA, 1 mM sodium orthovanadate, 0.1 mM PMSF, 1 mg/ml aprotinin, and
1 mg/ml leupeptin) (Sigma). The resulting suspension was centrifuged at 12,000 × g
for 20 min at 4 °C, and supernatants were collected and used for SDS-PAGE.
Protein samples were normalised by BCA protein assay (Pierce), and denatured by
the addition of 5× SDS sample buffer containing 0.2 M DTT and heated at 95 °C
for 10 min. 20 µg sample protein was loaded per well and samples were resolved on
4–12% gradient Bis-Tris gels (Invitrogen). Transfer was done for 60 min onto
PVDF membranes using mini-blot modules as per the manufacturer’s instructions
(Invitrogen). Membranes were blocked in 5% (w/v) dried milk in Tris-buffered
saline-Tween (0.05% v/v) (TBST) for 1 h at room temperature. Membranes were
then incubated with primary antibody (concentrations mentioned in Supplemen-
tary Table 1) diluted in 5% milk/TBST overnight at 4 °C, followed by incubation in
the appropriate HRP-conjugated secondary antibody for 1.5 h at room tempera-
ture. Blots were washed in TBST (4 × 10 min), incubated in LumiGloTM ECL
Reagent (Cell Signaling Technology) for 1 min, and imaged by chemiluminescence
using the Amersham imager. Quantification of the blots was performed using
ImageStudio Lite. Briefly, individual bands were quantified for relative intensity of
signal, and then normalized to loading control protein signal (e.g., β-Tubulin).
Uncropped blots are presented in the Source Data File.
Site-directed mutagenesis. Catalytic mutant of murine Arginase II plasmid
(pCMV-SPORT6-Arg-2) were obtained by a two‐step PCR using the QuickChange
site‐directed mutagenesis kit (Agilent, 210518) using primers indicated in Sup-
plementary Table 2. Following mutagenesis, the product was combined with
competent E.coli XL10 Gold cells (100 μL) on ice and incubated for half hour.
Following heat shock at 42 °C for 30 s, cells were re-incubated on ice for 2 min,
with subsequent addition of pre-warmed LB broth and incubation at 37 °C, shaking
for 1 hour to allow recovery prior to streaking on LB-Agar plates and growth
overnight. Following overnight growth, colonies were selected and streaked on a
grid plate as well as used as template DNA for a colony PCR. After emergence of
colonies, a single colony was selected for purification, followed by growth in a
starter culture and inoculation into 150 ml and midi prep of the plasmid using
Plasmid Midi Kit (Qiagen, 12143) as per the manufacturer’s instructions. Mutant
was confirmed using Allele-specific oligonucleotide (ASO) PCR and sequencing
from Source Bioscience. For ASO-PCR, a KAPA2G master mix was made for the
wild-type and mutant in PCR tubes. 1 ng/µl plasmid DNA was added to the master
mix. The PCR product was diluted in Agarose gel (6×) glycerol based sample buffer
and ran on a 2% (w/v) agarose gel to confirm mutagenesis.
Confocal microscopy. BMDMs were plated at 5 × 105 seeding density on µ-Dish
35 mm, high Glass Bottom (Ibidi, Germany) and maintained overnight at 37 °C in
a 5% CO2 atmosphere. Cells were stimulated at concentrations as described earlier.
After 24 h stimulation, cell samples (from individual wells) were taken for imaging.
Thirty minutes before the indicated time, cells were loaded with MitoTracker Red
CMXRos (Life technologies) at a final concentration of 50 nM. Cells were washed
with DPBS, replaced with fresh complete DMEM and observed in a Leica
SP8 scanning Confocal (Wetzlar, Germany), with a ×63 immersion objective.
Images were analysed with the Image-J software (National Institutes of Health,
Bethesda, MD). For Image-J analysis, mitochondrial length of more than 50
mitochondrial particles per cell was measured in over 25 cells per experimental
condition, out of three independent experiments. Mitochondria were then divided
into three different categories, based on length, as mitochondria of less than 1 µm,
1–3 µm, and greater than 3 µm, as described by ref. 30.
Luciferase assay. The full-length mouse Arg2 3′UTR (270 bp) was amplified using
Q5 High-Fidelity DNA Polymerase (NEB) and inserted into XhoI-digested pmir-
GLO vector (Promega) using the GenBuilder Cloning Kit (Genscript). Plasmids
were isolated from bacterial cultures with the Plasmid Midi Kit (Qiagen, 12143)
and the fidelity of the resulting construct (i.e., pmir_Arg2) was confirmed by
sequencing. The sequences of cloning and sequencing primers are reported in
Supplementary Table 2.
Raw 264.7 cells were seeded in a 96-well plate at a final density of 80,000 cells/
well and incubated for 24 h. Cells were then co-transfected with 100 ng of
pmir_Arg2 and either mirVana™ miR-155-5p mimic (25 nM, ID MC13058,
ThermoFisher Scientific) or inhibitor (50 nM, ID MH13058, ThermoFisher
Scientific) in serum-free DMEM using TransIT-X2 Dynamic Delivery System
(Mirus) as transfection reagent. Luciferase activity was assessed at 24 hours after
transfection using Dual-Luciferase Reporter Assay (Promega, E1910) according to
the manufacturer’s instructions. RLU (relative luciferase units) expressed as mean
value of the firefly luciferase/Renilla luciferase ratio of three independent
experiments performed in triplicate were used for statistical analyses.
Real-time polymerase chain reaction. Total RNA was isolated using the Qiagen
RNeasy Plus Mini kit (Sigma, 74106) and quantified using a Nano-Drop 1000
Spectrophotometer (Thermo Scientific Fisher). cDNA was prepared using 50–100
ng/μl total RNA using a high capacity cDNA reverse transcription kit (Applied
Biosystems, 4368814), according to the manufacturer’s instructions. Primers were
designed using the NCBI database (https://ncbi.nlm.nih.gov/tools/primer-blast)
and provided by Sigma. Please refer to Supplementary Table 2 for list of primers
used. Real-time quantitative PCR (RT-PCR) was performed on cDNA, diluted 1 in
2 with RNAase-free water, using SYBR Green probes on a 7900 HT Real-Time PCR
System (Applied Biosystems). Fold changes in expression were calculated by the
Delta-Delta (ΔΔ) Ct method using 18s as a control for mRNA expression. All fold
changes were normalised to untreated/non-targeting controls.
Cytokine measurement. For cytokine measurements, cells were stimulated as
indicated and supernatants removed and analysed for mouse IL-6, TNF, IL-10 and
IL-1β using Enzyme-linked Immunosorbent Assay (ELISA) ((DuoSet, R&D,
DY406 (IL-6), DY410 (TNF), DY417-05 (IL-10), DY401-05 (IL-1β)) with absor-
bance read using a microplate reader at 450 nm and compared against a standard
curve. Alternatively, the cytometric bead array (CBA), mouse inflammation kit (BD
Biosciences, 339199) was used to examine a panel of cytokines for in vivo
experiments, according to manufacturers’ instructions. Sample data for CBA was
acquired using Attune NxT Flow Cytometer with recommended voltage settings
for PE and APC-Cy7.
Arginase assay. Arginase activity was determined in BMDM and Raw 264.7 using
the Arginase Activity Assay Kit (Sigma, MAK112-1KT) following manufacturer’s
protocols. Briefly, cells were lysed in low-stringency lysis buffer followed by the
addition of arginine substrate buffer (provided in kit) and incubated at 37 °C for 2
h, after which time the reaction was stopped by the addition of Urea Reagent. Plate
was incubated for a further 1 h at room temperature, followed by determination of
absorbance at 430 nm. Arginase activity in μmol/minute was calculated as directed
by the manufacturer based on the absorbance of a 1 mM urea standard. Specific
activity (μmol/min/mg) was calculated following the determination of protein
concentration in cell lysates by BCA assay (ThermoFisher Scientific, 10678484).
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Greiss assay. NO production was measured using the Griess Reagent (Sigma) by
addition of reagent to sample supernatants in a 1:1 ratio. Absorbance in culture
media was detected by a plate reader at 540 nm and compared against a
standard curve.
Fumarate assay. BMDM were plated in 6-well plates at 3 × 106 cells/well in
complete DMEM and 10% (v/v) L929 media. Cells were collected by centrifugation
and sonicated for 10 s at amplitude 35% in an appropriate volume of cold buffer
containing 50 mM potassium phosphate (pH 7.5) and protease inhibitor cocktail
tablet (Roche). The assay was then performed according to the manufacturer’s
instructions of the ChromaDazzle Fumarate Assay kit (AssayGenie, BA0110) and
absorbance was read at 565 nm.
Succinate assay. BMDM were plated in 6-well plates at 3 × 106 cells/well in
complete DMEM and 10% (v/v) L929 media. Cells were collected by centrifugation
and lysed in an appropriate volume of assay buffer provided and protease inhibitor
cocktail tablet (Roche). The cells were centrifuged at 10,000 × g for 5 min and
supernatant was collected for assay. The assay was then performed according to the
manufacturer’s instructions of the Assay kit (Abcam, ab204718) and absorbance
was read at 450 nm.
Flow cytometry. BMDMs were seeded in non-tissue-culture plates and stimulated
as described above. Cells were stained with MitoTracker Green (for total mito-
chondrial mass) and MitoTracker Red CMXRos (for mitochondrial membrane
potential) or MitoSOX (for mitochondrial ROS) according to manufacturer’s
instructions (Invitrogen) in combination with Live/Dead stain (eBioscience™ Fix-
able Viability Dye eFluor™ 780). For flow cytometry analysis, data (10,000 events
per sample) was acquired with the Attune NxT Flow Cytometer and analysed with
FlowJo v10 software (TreeStar). A flow gating strategy is provided in Fig. 5 of
Supplementary Information.
ImageStream. 1–2 × 106 BMDM or Raw 264.7 cells were collected in a round-
bottom 96-well plate, washed with ice-cold DPBS and resuspended in 100 µl of 4%
paraformaldehyde (PFA) fixation buffer. Cells were incubated at 37 °C for 15 min,
after which they were washed twice with PBS-T (10 min incubation between
washes). This was followed by resuspension in ice-cold methanol and incubation at
−20 °C for 15 min. The cells were washed again twice with PBS-T, and resus-
pended in blocking buffer (5% goat serum; 0.3% Triton-X100 in PBS) at room
temperature for 1 h. Cells were briefly spun, the blocking buffer was removed and
the antibody cocktail was added as required (1:100 or 1:200 dilution in blocking
buffer), and incubated overnight at 4 °C. The following day the cells were spun,
rewashed three times with PBS-T, and Alexa-fluor fluorescent secondary antibody
cocktail was added (diluted in blocking buffer at 1:200 concentration). The cells
were incubated with the secondary antibody for 1 h in the dark at RTP, after which
they were washed twice with PBS-T. Finally, the cells were resuspended in 50 μl of
PBS with 600 nM DAPI (Invitrogen). For imaging, an ImageStream Mk-II cyt-
ometer (Amnis Inc, Seattle, USA) was used. The ImageStream was equipped
with 488, 658, and 405 nm laser sources with variable laser power (from 20 to
200 mW for the 488 nm laser and from 20 to 100 mW for the 658 nm laser) and a
brightfield light source. Files of 1000–5000 events were acquired for each
sample and 100–200 events were acquired for single fluorochrome controls.
Additional single colour control files were collected in the absence of brightfield
illumination for use in creating the compensation matrix with IDEAS software
(Amnis, Seattle, USA). The calculated compensation matrix was applied to all files
to correct for spectral crosstalk. The resulting compensated cytometry data were
further analysed with the IDEAS software program. Gating of cell events with the
area and aspect ratio was used to eliminate debris (low area) and multi-cellular
events (large area, high aspect ratio) from further analysis. After defining single,
focused cells, a colocalization program was run using the IDEAS software to
check for localization of Arg2 at the mitochondria by gating an Arg2 and Tom20
double-positive population. The software was then set to plot results for median
bright detail similarity (BDS) and compared to the BDS of a control sample
containing colocalization score for two known mitochondrial proteins (Tom20 and
Hsp60).
Metabolic flux analysis. Cells were plated at 5 × 104 cells/well (BMDMs) and 3 ×
104 cells/well (Raw 264.7) on an XFe96-well plate (Agilent) in complete DMEM
(+10% L929 supernatant in media for BMDM). Cells were treated and stimulated
accordingly. A utility plate containing the injector ports and probes was filled with
calibrant solution (200 μl/well) and placed in a CO2-free incubator at 37 °C over-
night. Following 24 h stimulation, complete DMEM was removed from cells and
replaced with XF assay media pH 7.4 (Agilent) at 175 μl/well. The XF assay media
was supplemented with 10 mM glucose, 1 mM pyruvate and 2 mM glutamine
(Sigma). The cell culture plate was then placed in a CO2-free incubator for 45 min.
Oligomycin (ATPase inhibitor, 1 μM), Carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone (FCCP) (0.9 μM) and Rotenone/Antimycin A
(0.5 μM) were added to the appropriate ports of the utility plate for a standard
MitoStress test according to instruction manual (Agilent, 103015-100). This plate
was run first on the flux analyser for calibration. Once complete, the utility plate
was replaced with the cell culture plate and run on the real-time Seahorse XFe96
analyzer for 1 h 30 min using the software’s MitoStress template program. The
OCR values for Raw 264.7 were normalised using absorbance readings obtained
from a protein quantification BCA assay (Pierce). Data were analysed using the
Wave software.
Complex-mediated respiration. For customised assays to measure individual
complex I (NADH-linked) and complex II (FADH2-linked) specific respiration
status in intact mitochondria, cells were resuspended in MAS buffer (70 mM
sucrose, 220 mM mannitol, 10 mM KH2PO4, 5 mM MgCl2, 2 mM HEPES and 1
mM EGTA, and 0.2% fatty-acid free BSA). The utility plate injector ports were
loaded with complex I or complex II specific substrates. Final concentrations/well
of complex-I specific substrates was 2.5 mM glutamate and 2.5 mM malate; and
complex-II specific substrate was 2.5 mM succinate (all from Sigma). After cali-
bration of utility/injector plate, right before inserting cell-plate in the machine, cells
were supplemented with 4 mM ADP, 0.5 µM Rotenone and 10 µg/ml digitonin.
The assay was run for 30 min and included three initial pre-injection measure-
ments and three post-injection measurements. Changes in OCR upon substrate
injection were calculated as an increase in percentage from pre-injection OCR
levels that were at baselined at 100%.
MTT assay. BMDMs were seeded at 5 × 105 cells/ml in 96-well plates and left
unstimulated or stimulated with 100 ng/mL LPS or LPS+ IL-10 for 24 h. Succinate
dehydrogenase activity was assessed by yellow 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) reduction to purple formazan. Cells were
incubated with 1 mg/mL MTT (Sigma) for 3 h at 37° C and 5% CO2 and subse-
quently, the media was aspirated off so the cells could be lysed with dimethyl
sulfoxide (DMSO). Absorbance of soluble formazan was measured spectro-
photometrically at 590 nm and background signal measured at 650 nm was sub-
tracted from this value for each sample. Cells were also treated for 24 hours with
10 mM of the SDH inhibitor dimethyl malonate (DMM) (Sigma) were included as
a control.
Spectrophotometric CII specific activity. BMDM stimulated as indicated and
cells were scraped and centrifuged at 200 × g for 5 min. Cell pellets were homo-
genized using a glass 2 ml dounce homogenizer with 25 strokes before freeze
thawing of lysates three times using liquid nitrogen. For CII activity, between 0.1
and 0.5 mg of cell lysate was added to a 1 ml cuvette containing 25 mM phosphate,
1 mg/ml fatty acid–free BSA, 0.3 mM KCN, 20 mM succinate and 75 µM 2,6-
Dichlorophenolindophenol (DCPIP) (Sigma). Samples were incubated for 10 min
at 37 °C before reading baseline absorbance at 600 nm using a UV-VIS spectro-
photometer. Baseline measurements were taken for 3 min before the addition of
50 μM decylubiquinone (Sigma). The ΔOD was followed for 4–5 min before the
addition of 20 nM Atpenin A5 (Sigma), a specific inhibitor of CII, to observe
the CII insensitive rate. CII specific activity was calculated according to
the Beer–Lambert law using a molar extinction coefficient for DCPIP of
19.1 mM cm−1. Citrate synthase activity was measured to account for mitochon-
drial content of samples and to normalize CII enzymatic rates. For citrate synthase
activities, 0.1–0.5 mg cell lysate was added to a 1 ml cuvette containing 100 mM
Tris pH 8.0 with 0.2% V/V Triton X-100, 100 μM DTNB (ThermoFisher Scien-
tific), and 300 μM Acetyl CoA (Sigma). Baseline absorbance was read at 412 nm for
3 min before initiating the reaction by the addition of 500 μM oxaloacetate. The
ΔOD was followed for 4 min. Citrate synthase specific activities were calculated
according to the Beer–Lambert law using the molar extinction co-efficient of
DTNB of 13.6 mM cm-1. CII specific activity was expressed as a ratio to citrate
synthase specific activity.
Statistical analysis. GraphPad Prism 8.00 (GraphPad Software) was used for
statistical analysis. A one-way ANOVA test was used for the comparison of more
than two groups, with Tukey or Sidak’s test for multiple comparisons. Analysis of
data with two or more factors were analysed by a two-way ANOVA with the
Sidak’s test for multiple comparison. A two-tailed Student’s t-test was used when
there were only two groups for analysis. By visual checking of normality dis-
tribution plots, either parametric tests were performed, or Mann–Whitney non-
parametric equivalents were employed where Shapiro–Wilks distribution was
violated (p > 0.05). All error bars represent SEM. Significance was defined as *p <
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Any specific statistical tests and
details of ‘n’ numbers done for experiments are listed under the corresponding
figures.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The gene expression datasets generated by the Affymetrix array have been deposited in
GSE under accession code GSE151835. The authors declare that all other data are
available in the article and Supplementary information files. Source data are provided
with this paper.
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